2
Articles Count
747
Viewing Count
Shi Yingzi

PharmaDJ reporter.

Do NMPA Approvals Cause Share Prices to Rise?
Shi Yingzi · 2 months ago
three fourths of stocks to rise on the day of approval.
Further information
Feature
China Approved its First Cell Therapy
Shi Yingzi · 2 months ago
On June 22, NMPA green-lighted Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B cell lymphoma.
Further information
News

Personal Information

Email:

shi.yingzi@pharmadj.com

Copyright © 2016-2021 PharmaDJ .All Rights Reserved.   Suggestions and feedback: Support@PharmaDJ.com   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement